Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We performed a meta-analysis of cholinesterase inhibitors for patients with Lewy body disorders, such as Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. METHODS: The meta-analysis included only randomized controlled trials of cholinesterase inhibitors for Lewy body disorders. RESULTS: Seventeen studies (n = 1798) were assessed. Cholinesterase inhibitors significantly improved cognitive function (standardized mean difference [SMD] = -0.53], behavioral disturbances (SMD = -0.28), activities of daily living (SMD = -0.28), and global function (SMD = -0.52) compared with control treatments. Changes in motor function were not significantly different from control treatments. Furthermore, the cholinesterase inhibitor group had a higher all-cause discontinuation (risk ratio [RR] = 1.48, number needed to harm [NNH] = 14), discontinuation due to adverse events (RR = 1.59, NNH = 20), at least one adverse event (RR = 1.13, NNH = 11), nausea (RR = 2.50, NNH = 13), and tremor (RR = 2.30, NNH = 20). CONCLUSIONS: Cholinesterase inhibitors appear beneficial for the treatment of Lewy body disorders without detrimental effects on motor function. However, a careful monitoring of treatment compliance and side effects is required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Relatives of the Impaired Elderly: Correlates of Feelings of Burden
Zarit, S. H., Reever, K. E., & Bach-Peterson, J. (1980) · The Gerontologist · doi:10.1093/geront/20.6.649 · Cited by 5,810
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers
Lippa, C. F., Duda, J. E., Grossman, M., Hurtig, H. I., Aarsland, D., Boeve, B. F., Brooks, D. J., Dickson, D. W., Dubois, B., Emre, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000256715.13907.d3 · Cited by 548
Tan, C.-C., Yu, J.-T., Wang, H.-F., Tan, M.-S., Meng, X.-F., Wang, C., Jiang, T., Zhu, X.-C., & Tan, L. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132690 · Cited by 484
Rolinski, M., Fox, C., Maidment, I., & McShane, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006504.pub2 · Cited by 418 · cited 1×
“The efficacy of ChEIs in managing patients with DLB, PDD, and cognitive impairment in PD (CIPD) was assessed in a Cochrane meta-analysis of 6 randomized controlled trials (RCTs) including 1263 patients (Rolinski et al., 2012).”
MethodDonepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study
Dubois, B., Tolosa, E., Katzenschlager, R., Emre, M., Lees, A. J., Schumann, G., Pourcher, E., Gray, J., Thomas, G., Swartz, J., et al. (2012) · Movement Disorders · doi:10.1002/mds.25098 · Cited by 202
Cited by
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Zuin, M., Cherubini, A., Volpato, S., Ferrucci, L., & Zuliani, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-16476-w · Cited by 72
d’Angremont, E., Begemann, M. J. H., van Laar, T., & Sommer, I. E. C. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.1835 · Cited by 71
Dementia with Lewy bodies: Challenges in the diagnosis and management
Chin, K. S., Teodorczuk, A., & Watson, R. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419835029 · Cited by 63
“…improvements in cognition (approximately two-point increase in MMSE score), neuropsychiatric symptoms and activities of daily living, benefits which might be maintained for up to 52 weeks (Aarsland et al., 2012; Ikeda et al., 2013; Matsunaga et al., 2015; Mori et al., 2012; Stinton et al., 2015).”
BackgroundChu, C.-S., Yang, F.-C., Tseng, P.-T., Stubbs, B., Dag, A., Carvalho, A. F., Thompson, T., Tu, Y.-K., Yeh, T.-C., Li, D.-J., et al. (2021) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2021.104474 · Cited by 14
Metadata
- Authors
- Matsunaga, S., Kishi, T., Yasue, I., & Iwata, N.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-07-28
- Volume
- 19
- Issue
- 2
- Pages
- pyv086
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W1825856938
- Cited by
- 64
- References
- 7
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.